Getting your Trinity Audio player ready...

Not too long ago Halberd Corporation (OTCMKTS:HALB) had been in the news after it announced that it had been provided with antibiotic-resistant bacteria samples by the CDC for research and testing work.

Trader Action:

The stock closed higher by 18.18% to $0.013 on the solid volume of 4.55 million shares, 3.30X its average volume.

On Wednesday, the company announced that it had been successful in eliminating such bacteria with the help of its extracorporeal laser eradication process. It should be noted that the process in question is still at the patent pending stage. It was a major new development for the company and it is going to be interesting to see if the Halberd stock experiences any action over the course of the coming days or not.

The research and testing had been conducted by the company in collaboration with student scholars and professors at Youngstown State University. In the past, the company had collaborated with the same university and had been successful in eradicating Gram Negative bacteria and Escherichia coli.

The latest research project was being managed by Dr. W Gregg Sturrus and Dr. Chester Cooper and they were being assisted by student scholars at the university. Both researchers praised the skills of the student scholars and the role that they had played in the success of the entire process.

On the other hand, the Chief Executive Officer, Chairman, and President of Halberd, William A Hartman spoke about the latest development as well. He noted the fact that the company’s methodology had been successful in eradicating the bacteria in a time span of less than 10 minutes compared well to the current standard of care that was available to patients.

He went on to note that the work that Halberd had managed to accomplish in eradicating antibiotic-resistant bacteria could eventually revolutionize the healthcare industry. It may be a good time to keep an eye on the Halberd stock in the coming days.